Skip to content
News
Anal Cancer
Bladder Cancer
Bone Cancer
Brain Cancer
Breast Cancer
Cancer of Unknown Primary
Cervical Cancer
Colon Cancer
Esophageal Cancer
Gastric Cancer
GIST
Head & Neck Cancer
Hodgkins Lymphoma
Leukemia
Acute Leukemia
Chronic Lymphocytic Leukemia
Chronic Myeloid Leukemia
Liver Cancer
Lung Cancer
Melanoma
Mesothelioma
Multiple Myeloma
Myelodysplastic Syndrome
MPN-PV-ET-MF
Neuroblastoma
Neuroendocrine Tumors
Non Hodgkins Lymphoma
Ovarian Cancer
Pancreatic Cancer
Prostate Cancer
Renal Cancer
Rectal Cancer
Sarcoma
Skin Care
Skin Cancer
Testicular Cancer
Thyroid Cancer
Triple Negative Breast Cancer
Uterine Cancer
About Us
Advertising
News
Newly Diagnosed
Treatment & Care
Survivorship
Join the Community
Newsletter
Search
Acute Leukemia
May 5, 2009
Compressed Dose-dense Induction with S-HAM Effective for AML Patients
Dr. C H Weaver MD
March 8, 2009
Prolonged Therapy for Poor-Prognosis Acute Myeloid Leukemia may Reduce Relapses
Dr. C H Weaver MD
March 8, 2009
Parental Use of Some Medications Associated with Incidence of Childhood ALL
Dr. C H Weaver MD
March 8, 2009
AML: New Test Helps Predict Relapse, Counter with More Intensive Therapy
Dr. C H Weaver MD
March 8, 2009
Recurrent AML: Antibody-Targeted Therapy, Gemtuzumab Ozogamicn, under FDA Review
Dr. C H Weaver MD
March 8, 2009
Gemtuzumab Ozogamicin A Safe & Effective Option for Patients with Relapsed AML
Dr. C H Weaver MD
March 8, 2009
E Coli-Asparaginase Superior to Erwinia-Asparaginase for Pediatric ALL
Dr. C H Weaver MD
March 8, 2009
Addition of Thalidomide Not Effective in AML or Myelodysplastic Syndromes
Dr. C H Weaver MD
March 8, 2009
Adolescents Have Improved Survival when Treated on Pediatric Protocols for ALL
Dr. C H Weaver MD
March 8, 2009
Additional Therapy Reduces Recurrences in Acute Myeloid Leukemia
Dr. C H Weaver MD
March 8, 2009
Intensified Induction Therapy May Reduce Relapses in APL
Dr. C H Weaver MD
March 8, 2009
C-Kit Levels Indicative of Response to Chemotherapy in AML
Dr. C H Weaver MD
Previous Page
1
…
3
4
5
6
7
…
9
Next Page
Loading Comments...
Write a Comment...
Email (Required)
Name (Required)
Website
